Tenax Therapeutics, Inc.
TENX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000034956
In the last 90 days, Tenax Therapeutics, Inc. insiders filed 6 open-market purchases and 0 sales; 111 institutions reported holding it in 13F filings for Q2 2026, worth $441.4M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Tenax Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +9 vs. Q2 2024
- Shares held
- 1.23M
- +1.21M (+6,532.1%) vs. Q2 2024
- Total value
- $4.25M
- +$4.20M (+7,453.8%) vs. Q2 2024
- New holders
- 13
- 3 more added
- Sold out
- 4
- 1 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TENX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 111 | $441.4M |
| Q1 2026 | 81 | $341.0M |
| Q4 2025 | 49 | $85.9M |
| Q3 2025 | 34 | $35.9M |
| Q2 2025 | 26 | $12.9M |
| Q1 2025 | 23 | $13.1M |
| Q4 2024 | 21 | $8.43M |
| Q3 2024 | 19 | $4.25M |
| Q2 2024 | 11 | $57.2K |
| Q1 2024 | 9 | $30.5K |
| Q4 2023 | 17 | $367.6K |
| Q3 2023 | 16 | $184.8K |
| Q2 2023 | 15 | $119.2K |
| Q1 2023 | 13 | $230.6K |
| Q4 2022 | 19 | $691.8K |
| Q3 2022 | 29 | $1.24M |
| Q2 2022 | 25 | $2.08M |
| Q1 2022 | 25 | $6.54M |
| Q4 2021 | 28 | $8.38M |
| Q3 2021 | 25 | $13.6M |
| Q2 2021 | 25 | $7.32M |
| Q1 2021 | 26 | $7.21M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Tenax Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 339,549 | $1.17M | 0.03% | +339,549 | New |
| VR Adviser, LLC | 208,333 | $720.8K | 0.04% | +208,333 | New |
| Vivo Capital, LLC | 208,333 | $720.8K | 0.06% | +208,333 | New |
| Adage Capital Partners GP, L.L.C. | 83,333 | $288.3K | 0.00% | +83,333 | New |
| Velan Capital Investment Management LP | 83,333 | $288.3K | 0.31% | +83,333 | New |
| Vestal Point Capital, LP | 83,333 | $288.3K | 0.02% | +83,333 | New |
| ADAR1 Capital Management, LLC | 62,423 | $216.0K | 0.04% | +62,423 | New |
| Stonepine Capital Management, LLC | 50,000 | $173.0K | 0.11% | +50,000 | New |
| Sphera Funds Management Ltd. | 29,166 | $100.9K | 0.02% | +29,166 | New |
| Price T Rowe Associates Inc | 24,000 | $84.0K | 0.00% | +24,000 | New |
| Dimensional Fund Advisors LP | 21,006 | $72.7K | 0.00% | +21,006 | New |
| Geode Capital Management, LLC | 18,390 | $63.6K | 0.00% | +7,349+66.6% | Added |
| Lynx1 Capital Management LP | 14,751 | $51.0K | 0.02% | +14,751 | New |
| Tower Research Capital LLC (TRC) | 1,693 | $5.86K | 0.00% | +732+76.2% | Added |
| UBS Group AG | 688 | $2.38K | 0.00% | −811−54.1% | Reduced |
| BlackRock, Inc. | 300 | $1.04K | 0.00% | +300 | New |
| Morgan Stanley | 260 | $900 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 28 | $97 | 0.00% | +12+75.0% | Added |
| Allworth Financial LP | 1 | $4 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −4,407−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −343−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |